Cryo-Cell avoided a delisting scare for now, but investors still face a 2027 countdown
Cryo-Cell avoided immediate delisting pressure. The harder test is whether its cord blood banking model can repair the balance sheet by 2027.
Pharma & Biotech
Pharma & Biotech
Could BioCardia, Inc.’s integrated platform overcome variability in cardiac regenerative treatments
Discover how BioCardia, Inc.’s Heart3D platform could reduce variability in cardiac cell therapy. Read the full analysis on what this means next.
Pharma & Biotech
Can China Medical University Hospital, Ever Supreme and SHINE OUT BIO reshape spinal cord injury repair?
New exosome therapy targets spinal cord injury repair non-invasively. Find out how this breakthrough could reshape neuroregenerative medicine.
Pharma & Biotech
Can Radix Regenerative turn BHRT, peptides and regenerative medicine into a scalable clinical partner model?
Radix Regenerative launches BHRT, peptide and regenerative medicine platform for U.S. clinics. Find out what this changes for providers.
Medical Devices & Diagnostics
Why Miracell’s SMART M-CELL FDA clearance could reshape the PRP and BMAC device market
Miracell has won FDA 510(k) clearance for SMART M-CELL. Read what it changes for PRP, BMAC, adoption, and regenerative medicine competition.
Pharma & Biotech
Can Aspect Biosystems turn government-backed biomanufacturing into a real regenerative medicine advantage?
Aspect Biosystems has secured a $280 million Canada-backed push in regenerative medicine. Read what it means for cellular therapy scale-up.
Pharma & Biotech
How XellSmart’s expanding IND portfolio is shaping the emerging market for CNS cell therapies
XellSmart’s iPSC-derived neuron therapy enters MSA-P trials after FDA and NMPA clearances. Discover what this means for regenerative neurology.
Pharma & Biotech
What Matricelf’s Parkinson’s spinout reveals about the future of cell based neurodegeneration therapies
Matricelf plans a subsidiary to commercialize its Parkinson’s therapy platform. Discover what this move signals for regenerative medicine and neurology innovation.
Pharma & Biotech
What Longeveron Inc.’s Phase 2b results mean for regenerative medicine in aging populations
Longeveron Inc. publishes Phase 2b laromestrocel data in frailty. Explore what it means for stem cell therapy and regulatory next steps.
Medical Devices & Diagnostics
What StimLabs’ DermaForm approval reveals about the future of regenerative wound care
StimLabs has secured FDA clearance for DermaForm, expanding its wound care portfolio. Find out what this changes for clinicians and the market.